ORGO News and Press, Organogenesis Holdings Inc. From 01/19/23

Summary Pharmaceuticals and biotechnology have the best value and quality scores in the sector. Healthcare providers are close to their historical baseline in valuation and quality. Fast facts on GNOM. 10 stocks cheaper than their peers in January. This monthly article...

CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today anno...

Summary The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Healthcare equipment and life science tools are overvalued by about 25% regarding the same metrics. Fast facts on IDNA. 10 stocks cheaper than their peers in No...

Summary In today's issue of the 1-Minute Market Report, I examine the market bounce since the October low, and highlight the areas of the market that are leading the way higher. On Thursday, for every stock that was down, there were 26 that were up. For the first time since August...

Organogenesis Holdings Inc. (ORGO) Q3 2022 Earnings Conference Call November 9, 2022 17:00 ET Corporate Participants Gary Gillheeney - President and Chief Executive Officer Dave Francisco - Chief Financial Officer Conference Call Participants Steve Lichtm...

Organogenesis Holdings press release ( NASDAQ: ORGO ): Q3 GAAP EPS of $0.00. Revenue of $116.9M (+2.7% Y/Y). For FY22, Net revenue of between $448 million and $465 million is expected, vs. consensus of $476.85M. For further details see: Organogenesis Hol...

CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, to...

Summary The market-wide sell-off has uncovered countless investment opportunities in the small and mid-cap healthcare arena. I have rediscovered Organogenesis trading at an incredible discount. Organogenesis has relied on PuraPly to accelerate growth while enjoying a diversified r...

Summary Pharmaceuticals and biotechnology have the best value and quality scores. Healthcare providers look undervalued relative to 11-year averages. Other healthcare industries don’t look attractive. Focus on a biotech ETF: GNOM (and why I don’t like it). ...

CANTON, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, t...